A bispecific antibody is a bifunctional antibody that contains two specific antigen binding sites. We cross-linked anti-CD3 monoclonal antibody with trastuzumab by chemical cross-linking, and obtained bi-specific antibodies for bi-directional recognition of tumor cells and lymphocytes. This bispecific antibody recognizes CIK cells via CD3 target and recognizes tumor cells via HER2 receptor.
In the final stage of DC-CIK cells culturing, the bispecific antibody was added and binds to the surface of CIK cells through anti-CD3 antibody. After transfusion, the cells were recruited to tumor cells through bispecific antibody, thereby enhancing the recognition and killing activity of CIK cells to tumor cells.
1. The preparation technique is relatively simple
2. The strong affinity of antibody to antigen greatly improves the DC-CIK cells on tumor